Semantic search

This page or action requires JavaScript to work. Please enable JavaScript in your browser or use a browser where it is supported, so that functionality can be provided as requested. For further assistance, please have a look at the noscript help page.

Search Clear all entries

ResultCodeExtra

To embed this query inline into a wiki page use the code below.

{{#ask: [[Outcome topic::Selenium]] [[Outcome name::DFS (Disease-Free Survival)||EFS (Event-Free Survival)||LFS (Local-Free Survival)||MFS (Metastases-Free Survival)||OS (Overall Survival)||PFS (Progression-Free Survival)||RFS (Recurrence-Free Survival)]]
 |?Outcome name
 |?Results after intervention
 |?Overall RoB judgment
 |format=table
 |limit=5
 |offset=5
 |sort=
 |order=asc
 |headers=plain
 |mainlabel=
}}

Results 6 – 10 previous 5 20 50 100 250 500 next 5

JSON CSV RSS RDF

Query log

{
    "query_string": "[[Outcome topic::Selenium]] [[Outcome name::DFS (Disease-Free Survival)||EFS (Event-Free Survival)||LFS (Local-Free Survival)||MFS (Metastases-Free Survival)||OS (Overall Survival)||PFS (Progression-Free Survival)||RFS (Recurrence-Free Survival)]]",
    "query_source": "SMWSQLStore",
    "query_time": "0.0071",
    "from_cache": false
}

	Outcome name	Results after intervention	Overall RoB judgment
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck	PFS (Progression-Free Survival)	After 12 months: No significant differences between arms	low risk
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology	OS (Overall Survival)	Median follow-up of 51 months (range 6-75): 5-year overall survival in the intervention arm was 91.9% vs. 83.1% in the control arm, no significant difference; p = 0.34	some concerns
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology	DFS (Disease-Free Survival)	Median follow-up of 49 months (range, 0-75): 5-year disease free survival in the intervention arm was 80.1% vs. 83.2% in the control arm, no significant difference; p = 0.74	some concerns
Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization	DFS (Disease-Free Survival)	10-year disease-free survival intervention arm 80.1% vs. control arm 83.2%; not significant; p = 0.65	high risk
Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization	OS (Overall Survival)	10-year overall survival intervention arm 55.3% vs. control arm 42.7%; not significant; p = 0.09	high risk